| Literature DB >> 32803172 |
Ehsan Ghorani1,2, James L Reading3,4, Jake Y Henry1,2, Marc Robert de Massy1,2, Rachel Rosenthal2, Virginia Turati5, Kroopa Joshi1,2, Andrew J S Furness6, Assma Ben Aissa1,2, Sunil Kumar Saini7, Sofie Ramskov7, Andrew Georgiou1,2, Mariana Werner Sunderland1,2, Yien Ning Sophia Wong1,2, Maria Vila De Mucha1,2, William Day1,2, Felipe Galvez-Cancino1,2, Pablo D Becker1,2, Imran Uddin8, Theres Oakes8, Mazlina Ismail8, Tahel Ronel8, Annemarie Woolston8, Mariam Jamal-Hanjani2, Selvaraju Veeriah2, Nicolai J Birkbak9, Gareth A Wilson9, Kevin Litchfield9, Lucia Conde10, José Afonso Guerra-Assunção10, Kevin Blighe10, Dhruva Biswas2, Roberto Salgado11, Tom Lund6, Maise Al Bakir9, David A Moore12, Crispin T Hiley2,9, Sherene Loi13, Yuxin Sun8, Yinyin Yuan6, Khalid AbdulJabbar6, Samra Turajilic6, Javier Herrero10, Tariq Enver5, Sine R Hadrup7, Allan Hackshaw14, Karl S Peggs1, Nicholas McGranahan2, Benny Chain8,15, Charles Swanton16,17,18, Sergio A Quezada19,20.
Abstract
Tumour mutational burden (TMB) predicts immunotherapy outcome in non-small cell lung cancer (NSCLC), consistent with immune recognition of tumour neoantigens. However, persistent antigen exposure is detrimental for T cell function. How TMB affects CD4 and CD8 T cell differentiation in untreated tumours, and whether this affects patient outcomes is unknown. Here we paired high-dimensional flow cytometry, exome, single-cell and bulk RNA sequencing from patients with resected, untreated NSCLC to examine these relationships. TMB was associated with compartment-wide T cell differentiation skewing, characterized by loss of TCF7-expressing progenitor-like CD4 T cells, and an increased abundance of dysfunctional CD8 and CD4 T cell subsets, with significant phenotypic and transcriptional similarity to neoantigen-reactive CD8 T cells. A gene signature of redistribution from progenitor-like to dysfunctional states associated with poor survival in lung and other cancer cohorts. Single-cell characterization of these populations informs potential strategies for therapeutic manipulation in NSCLC.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32803172 PMCID: PMC7115931 DOI: 10.1038/s43018-020-0066-y
Source DB: PubMed Journal: Nat Cancer ISSN: 2662-1347